SCHEMBL3884465

SCHEMBL3884465

CCOC(=O)CCCc1cccc(C)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.48
CYP4A11 Q02928 3/20 0.48
CYP1A2 P05177 3/20 0.46
ALOX5 P09917 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TOP2A P11388 1/20 0.45
TBXAS1 P24557 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
CYSLTR2 Q9NS75 2/20 0.44
CYSLTR1 Q9Y271 2/20 0.44
FAAH O00519 1/20 0.42
CYP4Z1 Q86W10 1/20 0.42
CYP4F11 Q9HBI6 1/20 0.42
CYP4F12 Q9HCS2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3886140 0.91 CYP4F2 (0.50) CYP4F2CYP4A11CYP1A2SMN1; SMN2TOP2A
SCHEMBL15821166 0.85 CYP4F2 (0.46) CYP4F2CYP4A11CYP1A2ALOX5CYP3A4
SCHEMBL24259216 0.82 KMT2A (0.47) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL7443875 0.81 CYP4F2 (0.51) CYP4F2CYP4A11CYP1A2ALOX5CYP3A4
SCHEMBL1135252 0.81 ALDH1A1 (0.48) CYP1A2CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL7205380 0.81 SMN1; SMN2 (0.47) CYP1A2CYP2C19SMN1; SMN2TBXAS1ALDH1A1
SCHEMBL1859504 0.79 CYP1A2 (0.57) CYP4F2CYP4A11CYP1A2ALOX5CYP3A4
SCHEMBL10896384 0.78 CYP4F2 (0.50) CYP4F2CYP4A11CYP1A2SMN1; SMN2TOP2A
SCHEMBL2958200 0.78 CYP4F2 (0.48) CYP4F2CYP4A11CYP1A2ALOX5CYP3A4
SCHEMBL20197039 0.78 CYSLTR2 (0.54) CYP4F2CYP4A11ALOX5SMN1; SMN2TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7511144-B2 Reverse hydroxamic acid derivatives KAKEN PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
EP-1431285-B1 REVERSE HYDROXAMIC ACID DERIVATIVES KAKEN PHARMA CO LTD (JP) 2009-01-07 EP disclosed
US-20040242928-A1 Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia STUDOR S.A. (LU) 2004-12-02 US disclosed
EP-1431285-A1 REVERSE HYDROXAMIC ACID DERIVATIVES Kaken Pharmaceutical Co., Ltd. (JP) 2004-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242928-A1 Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia TNF, RNASE1, IFNAR1 CYP4F2 3224/4885CYP4A11 2163/4885CYP1A2 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.